Abstract
Two double-blind, placebo-controlled, randomised, multicenter, multinational, parallel-group studies were carried out to identify the optimum dose of intranasal sumatriptan for the acute treatment of migraine. Study medication was taken as a single dose through one nostril in the first study, and as a divided dose through two nostrils in the second study. Totals of 245 and 210 patients with a history of migraine were recruited into the one-and two-nostril studies, respectively. In both studies, headache severity had significantly improved at 120 min after doses of 10–40 mg sumatriptan compared to placebo (P < 0.05) and the greatest efficacy rates were obtained with 20 mg sumatriptan. With 20 mg sumatriptan 78% and 74% of patients experienced headache relief in one- and two-nostril studies respectively. Sumatriptan was generally well tolerated, the most frequently reported event being taste disturbance. The results of the two studies are similar and indicate that administering sumatriptan as a divided dose via two nostrils confers no significant advantage over single-nostril administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armitage B, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, pp 129–132
Armitage B, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, pp 150–152
Armitage B, Berry G (1987) Statistical methods in medical research, 2nd edn. Blackwell, Oxford, pp 386–399
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265:2831–2835
Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31:291–294
Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 [Suppl 7]:1–96
Schipper NGM, Verhoef JC, Markus FWHM (1991) The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8:807–814
The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group (1991) A placebo-controlled study of intranasal sumatriptan for the acute treatment of migrane. Eur Neurol 31:332–338
The Oral sumatriptan Dose-defining Study Group (1991) Sumatriptan: an oral dose-defining study. Eur Neurol 31:300–305
The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine Eur Neurol 3l:306–313
The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316–321
Author information
Authors and Affiliations
Additional information
The publication committee members were as follows: Prof. C. Dahlöf Gothenburg; Prof. N. E. Gilhus, Bergen; Dr. V. Lüben, Giessen; Dr. R. Salonen, Tampere; Prof. J. M. Warier, Strasbourg; Ms E. Ashford, Glaxo Group Research Limited, Greenford; Mr. R. Dawson, Glaxo Group Research Limited, Greenford; Mrs D. Noronha Glaxo Group Research Limited, Greenford.Principal investigators were as follows: One nostril study France: Dr. N. Brion, Le Chesnay; Prof. G. Chazot, Lyon; Dr. P. Dano, Marseille; Prof. A. Destee, Lille; Dr. M. Schwob, Paris; Prof. J.M. Warter, Strasbourg. Germany: Dr. J. Brand, Konigstein; Dr. R. Enkelmann, St. Goar; Prof H. D. Langohr, Fulda; Dr. V. Lüben, Giesssen; Dr. M. Mockesch, Weinheim; Dr. H Pistauer, Preetz; Dr. Schimek, Giegen; Dr. E. Siegel, Munich. Norway: Dr. J. S. Aasen, Fredrikstad; Prof. N. E. Gilhus, Bergen; Dr. I. Monstad, Elverum; Dr. T. Mörland, Skien; Dr. K. Nestvold, Nordbyhagen; Dr. O. Roald, Oslo; Dr. R. Salvesen, Bodö; Prof. O. Sjaastad, Trondheim; Dr. B. Stadnes, Drammen; Dr. K. A. Tjörstad, Stavager.Two Nostril study Eire: Dr. A. Rynne, Dublin. Finland: Dr. M. Farkkila, Helsinki; Dr. H. Havanka, Kemi; Dr. T. Jolma, Pori; Dr. H. Kilpelainen, Savonlinna; Dr. E. Koivunen-Tapio, Jyvaskyla; Reunanen, Oulu; Dr. E. Sako, Turku; Dr. R. Salonen, Tampere. Sweden: Dr. B. Andersson, Gävle; Dr. C. Behring, Vasteras; Prof. C. Dahldf, Gothenburg; Dr. S. E. Eriksson, Falun; Dr. Hindfelt, Malmö; Dr. H. Hultberg, Osmo; Dr. F. Johansson, Umea; Dr. C. Muhr, Uppsala
Rights and permissions
About this article
Cite this article
Salonen, R., Ashford, E., Dahlöf, C. et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 241, 463–469 (1994). https://doi.org/10.1007/BF00919706
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00919706